Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Operating Leases (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Operating Leases for 4 consecutive years, with $2.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Leases changed N/A to $2.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.1 million, a N/A change, with the full-year FY2023 number at $462000.0, down 57.92% from a year prior.
  • Operating Leases was $2.1 million for Q3 2025 at Phathom Pharmaceuticals, up from $589000.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $2.1 million in Q3 2025 to a low of $133000.0 in Q2 2024.
  • A 4-year average of $935444.4 and a median of $1.1 million in 2022 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: crashed 57.92% in 2023, then skyrocketed 342.86% in 2025.
  • Phathom Pharmaceuticals' Operating Leases stood at $1.1 million in 2022, then plummeted by 57.92% to $462000.0 in 2023, then plummeted by 71.21% to $133000.0 in 2024, then surged by 1496.24% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Operating Leases are $2.1 million (Q3 2025), $589000.0 (Q2 2025), and $133000.0 (Q2 2024).